CollPlant Biotechnologies’ (CLGN) “Buy” Rating Reaffirmed at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of CollPlant Biotechnologies (NASDAQ:CLGN) in a research report released on Wednesday morning,Benzinga reports. The firm currently has a $14.00 price objective on the stock.

Separately, HC Wainwright reaffirmed a “buy” rating and set a $11.00 price objective on shares of CollPlant Biotechnologies in a research note on Friday, November 29th.

CollPlant Biotechnologies Trading Up 3.9 %

NASDAQ:CLGN opened at $3.69 on Wednesday. CollPlant Biotechnologies has a 12-month low of $3.24 and a 12-month high of $6.75. The firm has a market cap of $42.25 million, a price-to-earnings ratio of -2.40 and a beta of 0.86. The company’s 50-day moving average is $3.84 and its two-hundred day moving average is $4.29.

CollPlant Biotechnologies (NASDAQ:CLGN) last announced its quarterly earnings data on Wednesday, November 27th. The company reported ($0.38) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.37) by ($0.01). CollPlant Biotechnologies had a negative net margin of 2,680.00% and a negative return on equity of 77.05%. During the same quarter in the previous year, the company posted ($0.38) EPS. On average, equities research analysts forecast that CollPlant Biotechnologies will post -1.44 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the company. Benjamin Edwards Inc. acquired a new position in CollPlant Biotechnologies in the third quarter valued at $112,000. AMH Equity Ltd raised its holdings in shares of CollPlant Biotechnologies by 17.4% in the 4th quarter. AMH Equity Ltd now owns 116,500 shares of the company’s stock worth $419,000 after purchasing an additional 17,295 shares during the period. Finally, Villere ST Denis J & Co. LLC lifted its stake in shares of CollPlant Biotechnologies by 24.4% in the 3rd quarter. Villere ST Denis J & Co. LLC now owns 484,867 shares of the company’s stock valued at $2,407,000 after purchasing an additional 95,000 shares in the last quarter. 21.69% of the stock is owned by hedge funds and other institutional investors.

About CollPlant Biotechnologies

CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology.